Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience
Table 3
Clinical endpoints: survival, biochemical, and radiologic response. Survival analyses to compare whether survival advantage was associated with studied variables was performed using log-rank analysis.
n (%)
Median survival (months)
95% CI1
Died during follow-up
38 (74.5)
Overall survival (months)
10.2
7.5–13.0
Gender
51 (100)
M
35 (68.6)
10.6
3.4–17.8
F
16 (31.4)
10.2
0.0–22.0
Age
51 (100)
<50
10 (20)
5.3
0.8–9.8
>50
41 (80)
8.2
1.8–19.4
FUDR given with 90Y
Yes
17 (33.3)
17.0
6.7–27.3
No
34 (66.7)
8.2
4.2–12.3
Extrahepatic disease present
48 (100)
Yes
28 (58.3)
6.7
2.7–10.6
No
20 (41.7)
17.0
6.4–27.6
CEA response2
41 (100)
Yes
17 (41.5)
19.1
6.3–31.9
No
24 (42.9)
9.3
6.0–12.7
Radiographic Response3
31 (100)
Progressive Disease
7 (22.6)
13.6
7.4–19.8
Stable Disease
20 (64.5)
9.3
6.9–11.8
Partial Response
4 (12.9)
21.5
13.7–29.1
1 95% Confidence interval. 2 CEA response defined as a reduction in CEA ≥50% of pretreatment value. 3 RECIST criteria used to compare baseline measurement just prior to 1st treatment with radiologic response during 1–6 months follow-up imaging.
